ANIXA BIOSCIENCES INC Cash on Hand 2010-2022 | ANIX

ANIXA BIOSCIENCES INC cash on hand from 2010 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
ANIXA BIOSCIENCES INC Annual Cash on Hand
(Millions of US $)
2021 $36
2020 $9
2019 $6
2018 $5
2017 $7
2016 $3
2015 $7
2014 $6
2013 $1
2012 $1
2011 $3
2010 $1
2009 $2
ANIXA BIOSCIENCES INC Quarterly Cash on Hand
(Millions of US $)
2022-04-30 $32
2022-01-31 $35
2021-10-31 $36
2021-07-31 $37
2021-04-30 $38
2021-01-31 $14
2020-10-31 $9
2020-07-31 $9
2020-04-30 $6
2020-01-31 $6
2019-10-31 $6
2019-07-31 $6
2019-04-30 $7
2019-01-31 $6
2018-10-31 $5
2018-07-31 $5
2018-04-30 $5
2018-01-31 $5
2017-10-31 $7
2017-07-31 $6
2017-04-30 $5
2017-01-31 $2
2016-10-31 $3
2016-07-31 $4
2016-04-30 $5
2016-01-31 $6
2015-10-31 $7
2015-07-31 $8
2015-04-30 $8
2015-01-31 $10
2014-10-31 $6
2014-07-31 $6
2014-04-30 $3
2014-01-31 $3
2013-10-31 $1
2013-07-31 $1
2013-04-30 $1
2013-01-31 $2
2012-10-31 $1
2012-07-31 $1
2012-04-30 $2
2012-01-31 $3
2011-10-31 $3
2011-07-31 $4
2011-04-30 $2
2011-01-31 $1
2010-10-31 $1
2010-07-31 $1
2010-04-30 $2
2010-01-31 $2
2009-10-31 $2
2009-07-31 $2
2009-04-30 $2
2009-01-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.091B $0.001B
Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00